The discovery of an orally inactive peptide from snake venom established the important role of angiotensin converting enzyme (ACE) inhibitors in regulating blood pressure. This led to the development of Captopril, the first ACE inhibitor. When the adverse effects of Captopril became apparent new derivates were designed. Then after the discovery of two active sites of ACE: N-domain and C-domain, the development of domain specific ACE inhibitors began..
| Property | Value |
|---|
| dbpprop:abstract
|
- The discovery of an orally inactive peptide from snake venom established the important role of angiotensin converting enzyme (ACE) inhibitors in regulating blood pressure. This led to the development of Captopril, the first ACE inhibitor. When the adverse effects of Captopril became apparent new derivates were designed. Then after the discovery of two active sites of ACE: N-domain and C-domain, the development of domain specific ACE inhibitors began..
|
| dbpprop:hasPhotoCollection
| |
| rdf:type
| |
| rdfs:comment
|
- The discovery of an orally inactive peptide from snake venom established the important role of angiotensin converting enzyme (ACE) inhibitors in regulating blood pressure. This led to the development of Captopril, the first ACE inhibitor. When the adverse effects of Captopril became apparent new derivates were designed. Then after the discovery of two active sites of ACE: N-domain and C-domain, the development of domain specific ACE inhibitors began..
|
| rdfs:label
|
- ACE inhibitors drug design
|
| owl:sameAs
| |
| skos:subject
| |
| foaf:page
| |
| is owl:sameAs
of | |
![[RDF Data]](/statics/sw-cube.png)
